Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma Group (MREO) Net Income towards Common Stockholders: 2016-2024

Historic Net Income towards Common Stockholders for Mereo BioPharma Group (MREO) over the last 9 years, with Dec 2024 value amounting to -$43.3 million.

  • Mereo BioPharma Group's Net Income towards Common Stockholders rose 53.18% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.6 million, marking a year-over-year increase of 8.26%. This contributed to the annual value of -$43.3 million for FY2024, which is 46.79% down from last year.
  • Per Mereo BioPharma Group's latest filing, its Net Income towards Common Stockholders stood at -$43.3 million for FY2024, which was down 46.79% from -$29.5 million recorded in FY2023.
  • In the past 5 years, Mereo BioPharma Group's Net Income towards Common Stockholders ranged from a high of $17.2 million in FY2021 and a low of -$210.1 million during FY2020.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$42.2 million (2022), whereas its average is -$38.3 million.
  • Per our database at Business Quant, Mereo BioPharma Group's Net Income towards Common Stockholders crashed by 372.29% in 2020 and then skyrocketed by 108.16% in 2021.
  • Yearly analysis of 5 years shows Mereo BioPharma Group's Net Income towards Common Stockholders stood at -$210.1 million in 2020, then skyrocketed by 108.16% to $17.2 million in 2021, then tumbled by 346.13% to -$42.2 million in 2022, then spiked by 30.21% to -$29.5 million in 2023, then plummeted by 46.79% to -$43.3 million in 2024.